A Study of Participants With Advanced Non-Small Cell Lung Cancer Treated With Nivolumab in France After at Least One Prior Chemotherapy-based Treatment by Lung Initiative on Sequence Therapy

Bristol-Myers Squibb535 enrolled

Overview

The purpose of this trial is to describe the following, for each cohort, in real world conditions in France: * The characteristics and treatment sequence of patients treated with nivolumab * The effectiveness of nivolumab treatment * The safety profile of nivolumab * Treatment patterns (e.g. duration of treatment, subsequent treatments) of nivolumab * The patient-reported outcomes (PRO) in patients treated with nivolumab, at baseline and during follow up using the EuroQoL-5D-3L

Study Type

OBSERVATIONAL

Enrollment

535

Conditions

Lung Cancer

Eligibility

Sex: ALLMin age: 18 YearsHealthy volunteers:

Medical Language ↔ Plain English

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: * Pathologically confirmed diagnosis of advanced NSCLC * Whose physician has already decided to initiate a treatment with nivolumab for the treatment of advanced NSCLC according to the European label * Previously treated with at least one prior chemotherapy- containing regimen Exclusion Criteria: * Participants taking part in an interventional study for lung cancer treatment for which nivolumab is one of the investigational drugs * Participants with a diagnosis of another primary cancer within the past five years * Participants receiving IO within 12 weeks prior to nivolumab first infusion in the context of the present study Other protocol-defined inclusion/exclusion criteria apply

Locations (1)

Outcomes

Primary Outcomes

Time to treatment failure (TTF)

Time frame: Up to 3 years

Secondary Outcomes

Overall survival (OS)

Time frame: Up to 3 years

Progression-free survival (PFS)

Time frame: Up to 3 years

Time to next therapy (TTNT)

Time frame: Up to 3 years

Best overall response rate (BORR)

Time frame: Up to 3 years

Distribution of participant demographics characteristics: Age

Time frame: Index date (treatment initiation date for each individual patient

Distribution of participant demographics characteristics: Sex